Who
Pierre Legault
Director
Company insider
Files Form 4 as: Director, Syndax Pharmaceuticals; Director, Bicycle Therapeutics; Director, Urovant Sciences; Director, ARMO BioSciences; Director, Tobira Therapeutics; Chief Executive Officer, NephroGenex; Director, Nps Pharmaceuticals; Director, Forest Laboratories.
In numbers
- Trades disclosed
- 132
- Buys
- 0
- Sells
- 13
- Bought
- $0
- Sold
- $12.6M
- Companies
- 11
- Companies where not an officer
- 8
- First trade
- 9 Mar 2007
- Last trade
- 4 Feb 2026
- Last filed
- 6 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Feb 2026filed 6 Feb 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 5 Feb 2025filed 7 Feb 2025 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | BCYC Bicycle Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | BCYC Bicycle TherapeuticsBiotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 7 Feb 2024filed 9 Feb 2024 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —17,000 at $0.00 | filing |
| 2 Jan 2024filed 4 Jan 2024 | BCYC Bicycle Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 2 Jan 2024filed 4 Jan 2024 | BCYC Bicycle TherapeuticsBiotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 2 Feb 2023filed 3 Feb 2023 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 13 Jan 2023filed 13 Jan 2023 | SNDX Syndax Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 13 Jan 2023filed 13 Jan 2023 | SNDX Syndax Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 13 Jan 2023filed 13 Jan 2023 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $136K10,000 at $13.58 | filing |
| 13 Jan 2023filed 13 Jan 2023 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $270K10,000 at $27.00 | filing |
| 13 Jan 2023filed 13 Jan 2023 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $68K5,000 at $13.58 | filing |
| 13 Jan 2023filed 13 Jan 2023 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $135K5,000 at $27.00 | filing |
| 12 Jan 2023filed 13 Jan 2023 | SNDX Syndax Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —24,000 at $0.00 | filing |
| 12 Jan 2023filed 13 Jan 2023 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $227K24,000 at $9.47 | filing |
| 12 Jan 2023filed 13 Jan 2023 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $642K24,000 at $26.74 | filing |
| 3 Jan 2023filed 5 Jan 2023 | BCYC Bicycle Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,000 at $0.00 | filing |
| 3 Jan 2023filed 5 Jan 2023 | BCYC Bicycle TherapeuticsBiotechnology | SEC FORM 4 Code A | —11,500 at $0.00 | filing |
News
Syndax Pharmaceuticals, Inc. (SNDX) Investigation: Bronstein, Gewirtz ...SNDX · pr-inside.com · 22 Oct 2026Syndax Pharmaceuticals (SNDX) – Analysts' Recent Ratings ChangesSNDX · dailypolitical.com · 19 Oct 2026Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down – Here's WhySNDX · tickerreport.com · 15 Oct 2026
0 headlines in the last 90 days name Pierre Legault; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.